Antibody-based delivery of TNF to the tumor neo-vasculature potentiates the therapeutic activity of a peptide anti-cancer vaccine

In our recent publication in Clinical Cancer Research, we could demonstrate that the targeted delivery of TNF to CT26 tumors strongly synergizes with the immuno-dominant retroviral AH1 peptide vaccine.

#immunooncology #precisionmedicine #immunopeptidomics #cancer #vaccine #cancervaccine



要查看或添加评论,请登录

Tim Fugmann的更多文章

社区洞察

其他会员也浏览了